Vericel Corp (VCEL): R&D Expense
$27.56M
Year ended 2025-12-31
$29.17M
Trailing 12 months to 2026-06-30
+11.4%
3-year compound annual growth
+16.2%
5-year compound annual growth
+3.9%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $27.56M | +11.2% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $24.80M | +17.8% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $21.04M | +5.5% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $19.94M | +22.4% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $16.29M | +25.1% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $13.02M | -57.2% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $30.39M | +123.5% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $13.60M | +5.1% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $12.94M | -15.4% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $15.29M | -19.0% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $18.89M | -11.2% | 2018-03-05, From 2015-01-01 |
| 2014-12-31 | $21.26M | +40.8% | 2017-03-13, From 2014-01-01 |
| 2013-12-31 | $15.10M | -42.0% | 2016-03-14, From 2013-01-01 |
| 2012-12-31 | $26.02M | +22.0% | 2015-03-25, From 2012-01-01 |
| 2011-12-31 | $21.33M | n/a | 2014-03-13, From 2011-01-01 |
| No annual figure between 2010-06-30 and 2011-12-31. | |||
| 2010-06-30 | $12.66M | +12.1% | 2013-03-18, From 2009-07-01 |
| 2009-06-30 | $11.29M | n/a | 2012-03-15, From 2008-07-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Vericel Corp (VCEL) | 2025-12-31 | $27.56M | +11.2% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $93.77M | -8.9% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $300.27M | +8.7% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $201.58M | +171.6% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $80.28M | -11.6% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $58.05M | +8.3% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $274.87M | +23.7% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $149.06M | +17.8% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $228.30M | +9.5% |
Compare VCEL, ADPT, IOVA, VXRT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗